Abstract
Multiple myeloma (MM) is the second most common oncohematologic disease. Most patients are older than 65 years at diagnosis, and different therapeutic options are available depending on the age of the patient. For those younger than 65 years, autologous stem cell transplantation is the standard of care, whereas in older patients the better choice is conventional chemotherapy. The introduction of thalidomide, bortezomib, and lenalidomide, which target MM cells and the bone marrow microenvironment, has changed the therapeutic options in newly diagnosed patients with MM.
MeSH terms
-
Aged
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Boronic Acids / therapeutic use
-
Bortezomib
-
Clinical Trials as Topic
-
Humans
-
Lenalidomide
-
Middle Aged
-
Multiple Myeloma / diagnosis*
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / therapy*
-
Pyrazines / therapeutic use
-
Stem Cell Transplantation / methods
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Transplantation, Autologous / methods
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Boronic Acids
-
Pyrazines
-
Thalidomide
-
Bortezomib
-
Lenalidomide